geoguy78
Senior Member
Thought some might find this interesting. Lots of research is showing benefits for the liver with the new GLP-1/glucagon receptor agonists in the pipeline,
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide